6
|
Carlile GW, Robert R, Matthes E, Yang Q, Solari R, Hatley R, Edge CM, Hanrahan JW, Andersen R, Thomas DY, Birault V. Latonduine Analogs Restore F508del-Cystic Fibrosis Transmembrane Conductance Regulator Trafficking through the Modulation of Poly-ADP Ribose Polymerase 3 and Poly-ADP Ribose Polymerase 16 Activity. Mol Pharmacol 2016; 90:65-79. [PMID: 27193581 DOI: 10.1124/mol.115.102418] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 05/17/2016] [Indexed: 01/02/2023] Open
Abstract
Cystic fibrosis (CF) is a major lethal genetic disease caused by mutations in the CF transmembrane conductance regulator gene (CFTR). This encodes a chloride ion channel on the apical surface of epithelial cells. The most common mutation in CFTR (F508del-CFTR) generates a protein that is misfolded and retained in the endoplasmic reticulum. Identifying small molecules that correct this CFTR trafficking defect is a promising approach in CF therapy. However, to date only modest efficacy has been reported for correctors in clinical trials. We identified the marine sponge metabolite latonduine as a corrector. We have now developed a series of latonduine derivatives that are more potent F508del-CFTR correctors with one (MCG315 [2,3-dihydro-1H-2-benzazepin-1-one]) having 10-fold increased corrector activity and an EC50 of 72.25 nM. We show that the latonduine analogs inhibit poly-ADP ribose polymerase (PARP) isozymes 1, 3, and 16. Further our molecular modeling studies point to the latonduine analogs binding to the PARP nicotinamide-binding domain. We established the relationship between the ability of the latonduine analogs to inhibit PARP-16 and their ability to correct F508del-CFTR trafficking. We show that latonduine can inhibit both PARP-3 and -16 and that this is necessary for CFTR correction. We demonstrate that latonduine triggers correction by regulating the activity of the unfolded protein response activator inositol-requiring enzyme (IRE-1) via modulation of the level of its ribosylation by PARP-16. These results establish latonduines novel site of action as well as its proteostatic mechanism of action.
Collapse
Affiliation(s)
- Graeme W Carlile
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Renaud Robert
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Elizabeth Matthes
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Qi Yang
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Roberto Solari
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Richard Hatley
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Colin M Edge
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - John W Hanrahan
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Raymond Andersen
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - David Y Thomas
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| | - Véronique Birault
- Department of Biochemistry (G.W.C., R.R., Q.Y., D.Y.T.), Cystic Fibrosis Translational Research Center (G.W.C., R.R., E.M., Q.Y., J.W.H., D.Y.T.), and Department of Physiology (E.M., J.W.H.), McGill University, Montréal, Québec, Canada; GSK Respiratory Therapeutic Area Unit (R.S., R.H., V.B.), and R&D Platform Technology and Science (C.M.E.), GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom; Departments of Chemistry and Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, British Columbia, Canada (R.A.); Faculty of Medicine National Heart and Lung Institute, Imperial College London, London, United Kingdom (R.S.); Francis Crick Institute, London, United Kingdom (V.B.)
| |
Collapse
|
7
|
Hegde RN, Parashuraman S, Iorio F, Ciciriello F, Capuani F, Carissimo A, Carrella D, Belcastro V, Subramanian A, Bounti L, Persico M, Carlile G, Galietta L, Thomas DY, Di Bernardo D, Luini A. Unravelling druggable signalling networks that control F508del-CFTR proteostasis. eLife 2015; 4. [PMID: 26701908 PMCID: PMC4749566 DOI: 10.7554/elife.10365] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2015] [Accepted: 11/26/2015] [Indexed: 01/17/2023] Open
Abstract
Cystic fibrosis (CF) is caused by mutations in CF transmembrane conductance regulator (CFTR). The most frequent mutation (F508del-CFTR) results in altered proteostasis, that is, in the misfolding and intracellular degradation of the protein. The F508del-CFTR proteostasis machinery and its homeostatic regulation are well studied, while the question whether ‘classical’ signalling pathways and phosphorylation cascades might control proteostasis remains barely explored. Here, we have unravelled signalling cascades acting selectively on the F508del-CFTR folding-trafficking defects by analysing the mechanisms of action of F508del-CFTR proteostasis regulator drugs through an approach based on transcriptional profiling followed by deconvolution of their gene signatures. Targeting multiple components of these signalling pathways resulted in potent and specific correction of F508del-CFTR proteostasis and in synergy with pharmacochaperones. These results provide new insights into the physiology of cellular proteostasis and a rational basis for developing effective pharmacological correctors of the F508del-CFTR defect. DOI:http://dx.doi.org/10.7554/eLife.10365.001 Cystic fibrosis is a genetic disease that commonly affects people of European descent. The condition is caused by mutations in the gene encoding a protein called “cystic fibrosis transmembrane conductance regulator” (or CFTR for short). CFTR forms a channel in the membrane of cells in the lungs that help transport salt across the membrane. Mutated versions of the protein are not as efficient at transporting salts, and eventually this damages the lung tissue. As the damage progresses, individuals become very vulnerable to bacterial infections that further damage the lungs and may eventually lead to death. One of the reasons CFTR mutations are harmful is that they cause the protein to fold up incorrectly and remain trapped inside the cell. Cells have quality control systems that recognize and destroy poorly folded proteins, and so only a few of the mutated CFTR proteins ever make it to the membrane to move salts. New therapies have been developed that improve folding of the protein and/or help the CFTR proteins that make it to the membrane work better. But more and better treatment options are needed. Hegde, Parashuraman et al. have now tested drugs that control how proteins fold and move to the membrane to see how they affect gene expression in cells with the most common cystic fibrosis-causing mutation. These drugs are known to improve the activity of the CFTR mutant, but do so too weakly to be of clinical interest. The experiments revealed that the expression of a few hundred genes was changed in response the drugs. Many of these genes were involved in major signalling pathways that control how CFTR is folded and trafficked within cells. Next, Hegde, Parashuraman et al. tested drugs that inhibit these signalling pathways to see if they improve salt handling in the mutated cells. The experiments demonstrated that these inhibitor drugs efficiently block the breakdown of misfolded CFTR, or boost the likelihood of CFTR making it to the membrane, helping improve salt trafficking in the cells. The inhibitors produced even better results when used in combination with a known CFTR-protecting drug. The results suggest that identifying and targeting signalling pathways involved in the folding, trafficking, and breakdown of CFTR may prove a promising way to treat cystic fibrosis. DOI:http://dx.doi.org/10.7554/eLife.10365.002
Collapse
Affiliation(s)
- Ramanath Narayana Hegde
- Institute of Protein Biochemistry, National Research Council, Naples, Italy.,Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
| | - Seetharaman Parashuraman
- Institute of Protein Biochemistry, National Research Council, Naples, Italy.,Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
| | - Francesco Iorio
- Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
| | - Fabiana Ciciriello
- Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.,Biology and Biotechnology Department "Charles Darwin", Sapienza University, Rome, Italy.,Department of Biochemistry, McIntyre Medical Sciences Building, McGill University, Montréal, Canada
| | | | | | - Diego Carrella
- Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
| | | | - Advait Subramanian
- Institute of Protein Biochemistry, National Research Council, Naples, Italy
| | - Laura Bounti
- Institute of Protein Biochemistry, National Research Council, Naples, Italy
| | - Maria Persico
- Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
| | - Graeme Carlile
- Department of Biochemistry, McIntyre Medical Sciences Building, McGill University, Montréal, Canada
| | - Luis Galietta
- U.O.C. Genetica Medica, Institute of Giannina Gaslini, Genova, Italy
| | - David Y Thomas
- Department of Biochemistry, McIntyre Medical Sciences Building, McGill University, Montréal, Canada
| | - Diego Di Bernardo
- Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.,Department of Electrical Engineering and Information Technology, University of Naples Federico II, Naples, Italy
| | - Alberto Luini
- Institute of Protein Biochemistry, National Research Council, Naples, Italy.,Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.,Istituto di Ricovero e Cura a Carattere Scientifico SDN, Naples, Italy
| |
Collapse
|